US Bancorp
RAPP

US Bancorp’s Rapport Therapeutics RAPP Stock Holding History

US Bancorp’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$156 Buy
+5
New +$141 ﹤0.01% 4115
2025
Q2 		– Sell
-144
Closed -$1.44K – 4352
2025
Q1 		$1.44K Buy
+144
New +$1.87K ﹤0.01% 3932

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $401M AUM 284.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

US Bancorp's RAPP Position: Q1 2026 in Review

US Bancorp opened a new position in Rapport Therapeutics (RAPP) in Q1 2026: 5 shares worth $156. The stake represents ﹤0.01% of the portfolio and ranks #4115 among its holdings. This is a return to the name: US Bancorp previously reported a position in RAPP as recently as Q1 2025.

US Bancorp first reported a position in RAPP in Q1 2025 and has held it in 2 quarters since. The position peaked at $1.44K in Q1 2025. 147 funds tracked by Wall St. Rank hold RAPP as of Q1 2026.

  • US Bancorp held 5 shares of Rapport Therapeutics worth $156 as of Q1 2026.
  • Rapport Therapeutics was a new US Bancorp position in Q1 2026.
  • Rapport Therapeutics made up ﹤0.01% of US Bancorp's portfolio in Q1 2026, its #4115 holding.
  • US Bancorp first reported a position in Rapport Therapeutics in Q1 2025 and has held it in 2 quarters since.
  • US Bancorp's Rapport Therapeutics position peaked at $1.44K in Q1 2025.
  • 147 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q1 2026.

Based on US Bancorp's 13F filing for Q1 2026, filed 15 May 2026.